Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antidepressant
Biotech
Xenon pauses ph. 3 depression trials after psychosis events
The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events.
Nick Paul Taylor
Sep 18, 2026 6:03am
J&J-Contineum depression drug flunks another ph. 2 test
Sep 15, 2026 4:40am
Supernus links depression drug to fast responses in ph. 2 trial
Oct 18, 2024 9:17am
J&J's oral add-on aces phase 3 in major depressive disorder
May 29, 2024 11:55am
NRx keeps antidepressant's blockbuster hopes alive despite flop
Apr 30, 2024 11:16am
Neurocrine-Takeda antidepressant hits main mark in phase 2 trial
Apr 23, 2024 10:44am
